Cargando…

Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells

The aim of the present study was to investigate the inhibitory effects of dihydroartemisinin (DHA) on the primary tumor growth and metastasis of the human breast cancer cell line, MDA-MB-231, in vitro. The expression levels of urokinase-type plasminogen activator (uPA) were detected by immunocytoche...

Descripción completa

Detalles Bibliográficos
Autores principales:	ZHANG, SHUQUN, MA, YINAN, JIANG, JIANTAO, DAI, ZHIJUN, GAO, XIAOYAN, YIN, XIAORAN, XI, WENTAO, MIN, WEILI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997666/ https://www.ncbi.nlm.nih.gov/pubmed/24765140 http://dx.doi.org/10.3892/ol.2014.1918

Ejemplares similares

Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway
por: Ma, Xingcong, et al.
Publicado: (2016)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts
por: Chao, Shih-Chun, et al.
Publicado: (2011)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

Urokinase-type Plasminogen Activator Induces Neurorepair in the Ischemic Brain
por: Merino, Paola, et al.
Publicado: (2018)

Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice
por: Kida, Yoshifumi, et al.
Publicado: (2023)

Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report
por: Sugioka, Koji, et al.
Publicado: (2012)

Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.
por: Yamashita, J., et al.
Publicado: (1993)

Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
por: Kennedy, S., et al.
Publicado: (1998)

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis
por: Ma, Jinjin, et al.
Publicado: (2023)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

Inhibiting the urokinase‐type plasminogen activator receptor system recovers STZ‐induced diabetic nephropathy
por: Dal Monte, Massimo, et al.
Publicado: (2018)

High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer
por: Thielemann, Anna, et al.
Publicado: (2013)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
Publicado: (1987)

immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma
por: Skriver, L, et al.
Publicado: (1984)

Urokinase-type plasminogen activator: a new target for male contraception?
por: Qin, Ying, et al.
Publicado: (2015)

Urokinase-Type Plasminogen Activator Deficiency Promotes Neoplasmatogenesis in the Colon of Mice()()()
por: Karamanavi, Elisavet, et al.
Publicado: (2014)

Urokinase-type plasminogen activator promotes synaptic repair in the ischemic brain
por: Diaz, Ariel, et al.
Publicado: (2018)

Urokinase-type Plasminogen Activator Promotes Synaptic Recovery in the Ischemic Brain
por: Yepes, Manuel
Publicado: (2018)

Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator
por: Kromann-Hansen, Tobias, et al.
Publicado: (2017)

Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity
por: Stillfried, Gillian E, et al.
Publicado: (2007)

TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer
por: Majidzadeh-A, Keivan, et al.
Publicado: (2011)

N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer
por: Belfiore, Lisa, et al.
Publicado: (2020)

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
por: Witzel, Isabell, et al.
Publicado: (2014)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Aggregation and retention of human urokinase type plasminogen activator in the yeast endoplasmic reticulum
por: Agaphonov, Michael O, et al.
Publicado: (2002)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
por: Böcskei, Renáta M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_705vpjqkf5pocso3f36lvctd5l